🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — April 24, 2026

The April 24, 2026, SEC filings reveal heavy institutional conviction in mega-cap tech (AAPL, MSFT, NVDA, GOOG) across 25+ 13F-HRs totaling billions in AUM, with consistent top holdings signaling sustained bull market momentum despite no QoQ changes disclosed. FY2025 20-F annuals from Chinese ADRs show polarized results: strong revenue growth in 4/7 cases (Hesai +46% YoY, UP Fintech +56% YoY, Gravity +12% YoY, Ryde +40% YoY) but frequent margin compression or profitability misses (avg profit decline -10% where reported), alongside cash burn in growth names like Hesai (-41%). US firms report mixed Q1 2026: Intel revenues +7.2% YoY but $3.7B net loss from restructuring, First American +16% revenues/+69% net income, Flagstar Bank turnaround to $21M profit with C&I loans +9% QoQ. Proxy statements (10+ filings) cluster around June 2026 annual meetings for director elections, auditor ratifications, and comp approvals, with neutral sentiment but time-sensitive voting deadlines. Strategic M&A and pivots emerge in small caps (Bio Essence AI acquisition, Allbirds $50M convertible notes for NVIDIA GPUs), while capital allocation highlights News Corp's $1B buyback. Overall, portfolio-level trends favor tech overweight (tech names in 90% of 13Fs), but watch margin pressures in gaming/tech (5/8 reporters with contracting gross margins avg -200bps) and regulatory risks in ADRs.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 24, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (though heavily featuring financials, SPACs, and 13Fs), key themes include YoY earnings recovery in financials (avg net income +50-180% in 7 reporters like LVS +61%, UP Fintech +179%) offset by QoQ softness (e.g., Ponce -16%, Flagstar down), heavy institutional conviction in mega-cap tech (Apple, Nvidia, Amazon topping 25+ 13Fs), and clustered proxy events for AGMs/share votes in May-June. Aggregate trends show revenue surges (LVS +25% YoY, FAF +16%, UP +56%) with mixed NIM (expansions like Ponce +63bps YoY, compressions elsewhere), deposit/loan growth (avg +2-5% QoQ where reported), and active capital returns ($746M LVS buybacks, $33M FAF repurchases, FBIZ div +17%). No dominant insider trading patterns, but high ownership alignment (Lifetime Brands group 44.4%). Critical developments: Nasdaq delist risks (SHF), PRC regs (UP Fintech), M&A advances (Woori, Willow Lane). Implications: Bullish on gaming/fintech growth plays, caution on small-cap compliance/litigation, monitor AGMs for governance shifts amid tech-heavy portfolios signaling defensive positioning.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 24, 2026

Across 50 filings dated April 24, 2026, primarily from financial institutions and a handful of S&P 500 Healthcare names, Q1 2026 bank earnings dominate with mixed results: 7/10 banks showed YoY net income growth or turnarounds from losses (avg +25% YoY) but QoQ declines in 6/7 (avg -15%), driven by NIM expansions (avg +40bps YoY) offset by higher expenses and softer loan growth (avg -1% QoQ). Healthcare filings reveal positive funding momentum with Citius Pharma raising $5M for LYMPHIR launch, Lucid Diagnostics closing $16.8M offering, and Regeneron highlighting $14.3B 2025 revenues with $3.8B shareholder returns, contrasting neutral biotech proxies (Caribou, Rallybio). 20+ 13F-HR filings indicate portfolio managers overweight ETFs/tech (e.g., Apple, Nvidia top holdings across 15/20), with healthcare exposure in Amicus, Abbott, Masimo via select funds. Capital allocation trends favor buybacks/dividends (e.g., $33.5M repurchases at First American, $75M special dividend at FHLB SF), signaling confidence amid asset quality improvements (NPLs down in 4/7 banks). Key implication: Banking recovery YoY supports healthcare-adjacent stability, but QoQ softness flags deposit/loan pressures; monitor June biotech AGMs for governance catalysts.

16 high priority 34 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 24, 2026

Across 50 DEF 14A proxy statements filed on April 24, 2026, for US companies primarily in biotech, tech, energy, and financial services, overarching themes include robust 2025 revenue growth in 12+ firms (e.g., Adaptive Biotechnologies +55% YoY to $277M, nLIGHT +32% to $261M, Arlo ARR +28% to $330M+), strong capital returns via dividends and buybacks totaling billions (Nasdaq $1.2B returned, Comcast $11.7B, GoDaddy $1.6B FCF +19% YoY), and high insider/board ownership signaling alignment (Lifetime Brands 44.4%, Agios directors/execs 5.4%). Period-over-period trends show margin expansions in key players (nLIGHT gross margins to 30% from 17%, Columbia +30bps to 50.5%) but pockets of compression or declines (Columbia op income -24% YoY). Positive sentiment dominates (12/50 filings), with neutrals in governance-heavy summaries; biotech and tech sectors lead growth narratives amid AI/data center tailwinds. Portfolio-level patterns reveal 20+ companies highlighting record revenues or cash flow improvements, implying sector rotation opportunities into high-growth names ahead of June 2026 annual meetings. Market implications favor long positions in outperformers like Nasdaq and Comcast, while monitoring dilution risks from equity plan amendments in 15+ filings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 24, 2026

Three S-1 filings on April 24, 2026, signal robust IPO pipeline activity, blending a SPAC (InterPrivate), a financial services holding company IPO (Lincoln), and a resale registration with dilution risks (Laser Photonics). No direct period-over-period financial trends available across filings due to pre-IPO nature, but Lincoln's recent MarshBerry acquisition (Oct 31, 2025) excludes post-deal financials, potentially understating growth, while Laser references its Dec 31, 2025 10-K filed Apr 20, 2026, showing Intracoastal ownership at 147,867 shares as of Mar 31, 2026. Neutral sentiment dominates (2/3 filings), with mixed for Laser due to dilution overhang; materiality peaks at 10/10 for Lincoln. SPAC structure in InterPrivate offers $175M raise with sponsor commitment ($5.75M private units + $25K founder shares from Dec 10, 2025), highlighting management skin-in-game. Lincoln's controlled company status post-IPO preserves LILP partner voting control, while Laser's 2.9M share resale from warrants poses near-term pressure. Portfolio implication: Early positioning in IPOs could capture M&A/deal flow upside in SPACs/financials amid 2026 market thaw.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — April 24, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include robust revenue growth in select tech, energy, and financial firms (e.g., Reliance +9.8% YoY FY revenue, UP Fintech +56.3% YoY, Intel +7.2% YoY Q1), contrasted by margin pressures, losses, and operational challenges (e.g., Intel $3.1B operating loss, SHF Nasdaq delisting risk). M&A and capital market activity surged with mergers (Peoples Bancorp), offerings (Citius $5M raise), SPAC amendments (Willow Lane), and asset deals (Bio Essence $3.5M acquisition), while numerous Indian firms confirmed non-Large Corporate status under SEBI, signaling low debt burdens. Board/governance changes were prevalent (Wheels Up Delta designee, Easterly equity plan expansion), with proxy statements clustering for June 2026 AGMs. Portfolio-level trends show 12/20 financial reporters with YoY revenue growth averaging 25% but mixed PAT (e.g., Reliance +17.8%, GRAVITY -20.7%), highlighting resilience in consumer/digital segments amid energy weakness. Critical implications: monitor SPAC votes and delisting risks for short-term volatility; favor growth outperformers like UP Fintech amid PRC risks. Capital allocation leans toward buybacks/repurchases (First American $33.5M Q1, GoDaddy 10.2M shares), supporting shareholder returns despite selective dilution.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 24, 2026

Across 47 Q1 2026 earnings filings (primarily 10-Qs), mixed sentiment prevails with 45/47 rated mixed or negative, reflecting revenue growth averaging +8% YoY in large-caps (e.g., Intel +7%, LVS +25%, TI +19%) offset by profitability pressures from restructuring (Intel $4B charges), cost inflation (SkyWest fuel +59%), and impairments (Meritage $2.4M). Margin compression hits 18/47 companies (avg -100bps), particularly telecom (Charter video -9%) and homebuilders (Meritage -35% gross profit), while semiconductors (TI +19% rev, +31% NI) and energy services (Halliburton +129% NI) outperform. Capital allocation remains shareholder-friendly with buybacks/dividends in 35+ firms (e.g., Nasdaq $548M buybacks, LVS $746M), signaling management conviction amid 12/47 showing cash burn. Cash flow trends mixed: 22 improved YoY (e.g., Dow +$1B), 20 declined (e.g., Western Union -26%). Portfolio-level: Rotate from cyclicals (chemicals Dow -6% rev) to defensives (P&G +7% sales). Sector rotation opportunities in semis/energy; watch debt spikes (PMI short-term borrow +$5.5B). Actionable: Buyback-heavy names offer downside protection in volatile macro.

47 high priority 47 total filings
· daily

US SEC Trading Suspension Halt Orders — April 24, 2026

Across 7 US-listed microcap companies, a pervasive crisis of Nasdaq compliance dominates, with 6/7 filings citing Minimum Bid Price violations under Rule 5550(a)(2) after 30 consecutive business days below $1/share, signaling acute share price weakness and potential mass delistings to OTC markets. Triller Group faces an advanced delisting determination post-180-day cure failure and prior trading suspension (Dec 30, 2025-Apr 15, 2026), while Nuvve Holding risks imminent suspension on April 29, 2026, due to prior reverse splits (cumulative 250:1 ratio) rendering it ineligible for standard compliance periods. Mannatech stands out as the sole equity deficiency case ($5.223M deficit vs $2.5M requirement as of Dec 31, 2025), highlighting balance sheet deterioration without market value or net income alternatives. All filings carry negative sentiment (materiality 9-10/10), with no period-over-period financial improvements noted to support recovery; forward-looking plans (appeals, reverse splits) lack assurance of success. Portfolio-level pattern: No insider buying or capital returns (dividends/buybacks) amid board churn (SHF resignation/expansion) and litigation setbacks (SHF $3M registry at risk), implying low management conviction and high delisting cascade risk by Q4 2026. Market implications include liquidity evaporation, volatility spikes pre-suspension, and OTC discounts of 20-50% historically for similar cases.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 24, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is Nasdaq delisting risks from sub-$1 bid prices affecting 7 companies (Triller Group, SHF Holdings, Standard BioTools, Nuvve Holding, NexGel, Medicus Pharma, Zeo Energy), with compliance deadlines clustered around October 19-20, 2026, signaling widespread microcap distress. Counterbalancing this, 12 companies pursued liquidity enhancements via credit facility expansions or amendments (e.g., PDF Solutions +$30M to $70M revolver, Trane Technologies $1.5B new facility, AEVEX $375M total commitments), indicating proactive refinancing amid potential stress. Positive capital raises via equity offerings (e.g., Altimmune $211M net, Elmet IPO $109M net) and M&A (e.g., Peoples Bancorp acquiring Citizens National, Helix acquiring Hornbeck) suggest turnaround efforts, though mixed with litigation and defaults (Splash Beverage, urban-gro). No broad period-over-period revenue/margin trends available, but equity deficits (Mannatech -$5.2M vs $2.5M required) and contract terminations (Spire Global Can$71.8M potential lost) highlight deteriorating financials in outliers. Overall, portfolio-level pattern shows distress concentrated in Nasdaq-listed small caps, with credit actions providing near-term buffers but dilution risks from offerings; investors should prioritize monitoring delisting appeals and Q2 2026 catalysts for short opportunities.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — April 24, 2026

Across 38 filings on US executive and director changes dated April 24, 2026, the dominant theme is routine governance refreshment with 20+ resignations (mostly for personal reasons, term limits, or retirements, none citing disagreements), balanced by 15+ appointments of experienced leaders in aerospace, finance, ops, and CPG sectors. Positive sentiments prevail in 10 cases (e.g., strategic board adds at Wheels Up and Woodward), while 22 are neutral; banking peers show strong shareholder approvals for directors and equity plans amid ChoiceOne's YoY net income turnaround from -$13.9M loss to +$13.7M despite slight QoQ dip. No widespread insider selling or pledges noted; capital allocation favors equity incentives (e.g., PNC's 28M-share plan approved at 96.6%). Portfolio-level patterns indicate small-cap/biotech instability (e.g., 3 Scorpius directors out) vs. large-cap stability, with interim C-suite roles signaling near-term transition risks but opportunities in permanent promotions (e.g., Lee Enterprises). Market implications: monitor for strategic shifts in partnerships (Wheels Up-Delta) and M&A (Trump Media), as changes enhance expertise without major disruptions.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 24, 2026

Across 37 SEC filings on USA Board Room Changes dated April 24, 2026, the dominant theme is executive and board stability with 18 appointments/nominations of experienced leaders (e.g., Delta CFO to Wheels Up board, aerospace expert to Woodward), offset by 22 routine resignations/retirements not citing disagreements, signaling low discord but potential continuity risks in biotechs and small caps. Annual meetings in financials (PNC, Jeld-Wen, 1st Source, Easterly, Fifth Third) showed overwhelming director support (avg 94-99% For votes), equity plan approvals (e.g., PNC 28M shares, Easterly +2.875M shares), and exec comp ratification >90%, indicating strong governance confidence amid no YoY declines in vote turnout (e.g., Jeld-Wen 85.64% vs prior implied stable). C-suite shifts include 6 CEO/CFO/COO changes (e.g., permanent CEOs at Lee Enterprises, ALT5 Sigma; interims at Nine Energy, American Shared, Trump Media), with comp uplifts like +22.6% salary at American Shared signaling retention urgency. No explicit insider selling patterns or financial deteriorations (e.g., stable D/E ratios implied in utilities like TVA), but forward-looking catalysts include M&A at Trump Media and proxy filings April 24 (Wheels Up). Sectorally, financials exhibit portfolio-level strength (6/8 high materiality >6/10), biotechs show churn (7/37 neutral resignations), and positive sentiment (9/37) correlates with strategic hires boosting transformation narratives. Overall, actionable now: overweight stable financial boards, monitor biotech interim voids for governance discounts.

37 high priority 37 total filings
· daily

US Merger & Acquisition SEC Filings — April 24, 2026

The 11 filings reveal a vibrant US M&A and takeover landscape dominated by SPAC activities (7/11 filings), including fresh IPOs, extensions, leadership transitions, and conditional listings, alongside four high-impact acquisitions in robotics, defense, pharma, and real estate finance. Key period-over-period trends highlight explosive growth in acquired entities: ASA Robotics revenue +213% YoY to HK$1.6M with margins expanding +5040 bps to 60.5%, Ondas backlog surging 160% to $457M pro forma, and Apollo CRE realizing $2.2B cash post-portfolio sale at a premium to trading levels. M&A completions (International Endeavors, Telomir, Ondas, Apollo) deliver strategic synergies, backlog boosts, and liquidity, signaling portfolio-level conviction in tech/defense/pharma sectors. SPAC maneuvers indicate ongoing deal hunting amid tight timelines, with extensions and amendments buying time for business combinations. Overall, bullish sentiment prevails (6/11 positive), pointing to actionable opportunities in post-merger entities and de-SPAC catalysts, though leadership churn and listing risks warrant caution.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 24, 2026

Overnight SEC filings reveal heavy institutional accumulation in tech megacaps like NVIDIA, Apple, Microsoft, and Alphabet across 20+ 13F-HR reports from firms including Ninety One entities, IFM Investors, Chicago Capital, totaling billions in AUM with concentrated positions signaling sustained bullish conviction. Among operating companies, 20-F annual reports show divergent performance: strong growth in UP Fintech (revenues +56.3% YoY to $612M, net income +179%), Hesai Group (+46% to RMB 3.03B), Ryde (+40% to S$12.5M), offset by declines in BingEx (-10.7% to RMB 3.99B), Gravity (+11.9% but operating profit -9.4%), and Medicure (revenue +32% but net loss widened to $7.1M on COGS surge). US financials mixed with First American revenues +16.2% YoY and net income +68.6%, Flagstar Bank Q1 net income turnaround to $21M (from Q1 2025 loss), Intel revenues +7.2% but deeper Q1 loss on restructuring. Capital allocation highlights include News Corp's $1B buyback continuation and First American's $33.5M repurchases/$56.2M dividends; no insider transactions noted across filings. Proxy season ramps up with June 2026 annual meetings for Palantir, VAALCO, Lucid, Comstock. Broader themes: AI/compute pivots (Allbirds $50M notes for NVIDIA GPUs), nuclear energy registration (X-Energy), SPAC activity; implications favor tech/energy longs amid mixed earnings recovery.

16 high priority 34 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — April 23, 2026

This digest covers $528,988,381 in federal construction and infrastructure contract obligations across 6 awards from April 23, 2026 data, all civilian with 0 defense-related contracts. Dominant themes include VA hospital infrastructure (S.J. Amoroso $69.5M boiler plant, R.E.D. $39.8M upgrades) and DOI facilities/utilities (NW Construction $257.3M modification, Perini $42.3M wastewater). Highest-conviction bullish signal is S.J. Amoroso's $69.5M VA award (materiality 7/10) via full/open competition, signaling established position in institutional building construction. Key risk is pervasive high fixed-price execution across all contracts, with minimal outlays ($0 on four awards). Watch outlay progress and 2027 performance milestones amid neutral average signal strength of 4.8/10.

6 total filings
· daily

DHS Homeland Security Contracts — April 23, 2026

DHS awarded two civilian contracts totaling $129,158,323 in obligations during the April 23, 2026 period, with zero defense-related activity out of two awards. The dominant themes are U.S. Coast Guard construction via Whiting-Turner Contracting Company ($74,485,557 firm fixed-price delivery order) and FEMA preparedness training via Leidos, Inc. ($54,672,765 obligation, potential $85,196,410 ceiling). Both carry neutral signals (average strength 4.5/10), with the highest-conviction signal being steady revenue potential from Leidos' partially outlayed ($32,670,674) cost-plus contract. A key risk is Whiting-Turner's high execution risk under fixed-price terms with $0 outlayed to date on its June 2026-ending project. Investors should watch outlay progress and option exercises amid neutral sector momentum.

2 total filings
· daily

VA Healthcare & Services Contracts — April 23, 2026

The VA awarded $1,735,526,190 in healthcare and services contracts during the period, all civilian with 0/4 defense-related, dominated by Department of Veterans Affairs spending on IT hardware and hospital construction/infrastructure. Highest-conviction bullish signal is DELL FEDERAL SYSTEMS L.P.'s $1,590,136,261 award, representing 91.6% of total obligations and signaling strong VA tech procurement demand. S. J. AMOROSO CONSTRUCTION CO., LLC's $69,517,876 firm-fixed-price boiler plant contract adds construction momentum under full and open competition. Key risk is $0 outlays to date on the two largest construction awards (S. J. AMOROSO and R.E.D. CONSTRUCTION SERVICES, LLC), exposing high pricing risk amid multi-year performance periods.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 23, 2026

HHS contracts from April 23, 2026 total $277,577,764 in obligations, with 1/3 defense-related primarily through DLA Troop Support's $65M award for DoD pharmaceuticals. The dominant agency theme is HHS/BARDA biodefense and pharmaceutical procurement, led by Emergent BioDefense Operations Lansing LLC's $211.4M firm-fixed-price award for smallpox antiviral R&D. Highest-conviction signal is bullish on Emergent due to sole-source selection, $173.9M outlayed of $211.4M obligated, and potential $647.5M ceiling through 2032. Civilian HHS focus outweighs minor defense tie-in, but high pricing risk pervades all firm-fixed-price structures. Key watch item: Emergent options exercise and outlay progress beyond $173.9M toward 2028-10-01 current end.

3 total filings
· daily

New Federal Contractors — April 23, 2026

This one-day snapshot of 29 new federal contracts totals $3,864,631,168 in obligations, with only 1 defense-related award amid a dominant civilian agency focus (VA, HHS, Interior, NASA, DOL). Highest materiality goes to DELL FEDERAL SYSTEMS L.P.'s $1.59B VA contract (bullish, strength 7/10) and BOOZ ALLEN HAMILTON INC.'s $245M Interior IT delivery order (46% outlayed), signaling tech and construction strength in civilian spending. Emergent BioDefense's $211M HHS BARDA biodefense award (options to $647M) offers highest-conviction growth potential in biotech R&D. Key risk: 12 fixed-price contracts (e.g., S.J. AMOROSO's $70M VA boiler plant) carry high execution risk with many at $0 outlayed; watch option exercises and outlay progress amid CR uncertainty for Oct-Dec awards.

29 total filings
· daily

Significant Contract Modifications ($10M+) — April 23, 2026

These 29 significant contract modifications totaling $3,864,631,168 in obligations over April 23, 2026, are overwhelmingly civilian-focused (28/29 non-defense, with only DLA Troop Support's $65M HHS award for DoD pharmaceuticals qualifying as defense-related), highlighting steady but fragmented spending across HHS ($452M+), VA ($1.7B+ dominated by Dell), Interior ($544M+), and NASA. Dominant themes include healthcare services, construction/infrastructure, and IT/professional support, with no clear defense acceleration. Highest-conviction bullish signal is Dell Federal Systems L.P.'s $1.59B VA award, signaling massive tech exposure in veteran services. Key risk is execution on fixed-price contracts like Johnson Controls Government Systems LLC's $75.7M DOE ESPC ($0 outlayed, high risk over 25 years) and Whiting-Turner Contracting Company's $74.5M DHS build ($0 outlayed). Watch outlay progress on top awards amid potential CR uncertainty for future mods.

29 total filings
· daily

Contract Deobligations Alert — April 23, 2026

This Contract Deobligations Alert covers 29 contracts totaling $3,864,631,168 in obligations over April 23, 2026, with only 1 defense-related award amid 28 civilian contracts dominated by HHS ($392M+ across Emergent BioDefense, Maximus, Noridian, Pfizer), VA ($1.7B+ including Dell Federal $1.59B and S.J. Amoroso $69.5M), and Interior ($544M+ via Booz Allen $245M, NW Construction $257M). Highest-conviction bullish signal is Dell Federal Systems L.P.'s $1.59B VA award (materiality 8/10), underscoring tech/services durability despite deobligation context. Booz Allen Hamilton captures $285M across two Interior/DOE IT contracts, signaling consulting moat. Key risk: 12+ contracts at $0 outlayed (e.g., Whiting-Turner $74.5M DHS, S.J. Amoroso $69.5M VA) heighten execution uncertainty in fixed-price structures; watch outlay progress and option exercises amid CR vulnerability for recent awards.

29 total filings